Quick Take
Deciphera Pharmaceuticals (DCPH) has set terms for its proposed IPO, seeking to sell 6.25 million of common stock at a midpoint price of $16.00 per share.
Deciphera is a clinical-stage biopharmaceutical firm developing kinase inhibitor treatments for a variety of cancers.
Although its candidates are promising, the combination of very early stage trials, no existing investor IPO support, and a fairly high valuation means my opinion is to AVOID the IPO.
MG+M The Law Firm (MG+M) is pleased to announce that it has elevated attorneys Stephanie M. Chesney
Burns & Levinson announced today that well-known plaintiff employment litigator Beth R. Myers has joined the firm
BayCoast Bank is delighted to announce Nicole Almeida as Senior Vice President, Chief Diversity Officer (CDO)
BayCoast Bank is pleased to announce Robert Bergdoll of Attleboro, Massachusetts, as First Vice President Marketing Director
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2024 citybuzz
